secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001558370-23-010277
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AYTU Biopharma stockholders approve 2023 equity incentive plan and elect all director nominees
--------------------------------------------------------------------------------

- All five director nominees elected; For votes ranged 673,707–685,411, Withheld 304,133–315,837.
- 2023 Equity Incentive Plan approved: 632,357 For, 352,359 Against, 4,828 Abstain; 952,620 broker non-votes.
- Ratification of Grant Thornton as independent auditor approved: 1,754,922 For, 132,135 Against, 55,107 Abstain.
- Advisory vote on executive compensation approved (non-binding): 587,253 For, 383,698 Against, 18,593 Abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/0001558370-23-010277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023010277/aytu-20230518x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer